Julie A. Hutt

Julie A. Hutt

Auto-generated profile, based on publicly available information

Julie A. Hutt

Greenfield Pathology Services

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2021 in Toxicologic Pathology
Verified
Journal Article
Closed access
PDF file
JHJulie A. Hutt
Julie A. Hutt
BABasel T. Assaf
Basel T. Assaf
BBBrad Bolon
Brad Bolon
JCJoy Cavagnaro
Joy Cavagnaro
EGElizabeth Galbreath
Elizabeth Galbreath
LWLaurence O. Whiteley
Laurence O. Whiteley
Sequencing of the human genome and numerous advances in molecular techniques have launched the era of genetic medicine. Increasingly precise technologies for genetic modification, manufacturing, and administration of pharmaceutical-grade biologics have proved the viability of in vivo gene therapy (GTx) as a therapeutic modality as shown in several thousand clinical trials and recent approval of several GTx products for treating rare diseases and cancers. In recognition of the rapidly advancing knowledge in this field, the regulatory landscape has evolved considerably to maintain appropriate monitoring of safety concerns associated with this modality. Nonetheless, GTx safety assessment remains complex and is designed on a case-by-case basis that is determined by the disease indication and product attributes. This article describes our current understanding of fundamental biological principles and possible procedures (emphasizing those related to toxicology and toxicologic pathology) needed to support research and development of in vivo GTx products. This article is not intended to provide comprehensive guidance on all GTx modalities but instead provides an overview relevant to in vivo GTx generally by utilizing recombinant adeno-associated virus-based GTx—the most common in vivo GTx platform—to exemplify the main points to be considered in nonclinical research and development of GTx products.

1 May 1999 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Open access
PDF file
RTRamiro Toribio
Ramiro Toribio
CKCatherine W. Kohn
Catherine W. Kohn
ALAlan E. Lawrence
Alan E. Lawrence
JHJoanne Hardy
Joanne Hardy
JHJulie A. Hutt
Julie A. Hutt
"Thoracic and abdominal blastomycosis in a horse" published on 01 May 1999 by American Veterinary Medical Association.

22 May 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
JLJulie A. Lovchik
Julie A. Lovchik
DRDouglas Reed
Douglas Reed
JHJulie A. Hutt
Julie A. Hutt
FXFangfang Xia
Fangfang Xia
RSRick L. Stevens
Rick L. Stevens
TWTerry H. Wu
Terry H. Wu
Pneumonic tularemia is a highly debilitating and potentially fatal disease caused by inhalation of Francisella tularensis. Most of our current understanding of its pathogenesis is based on the highly virulent F. tularensis subsp. tularensis strain SCHU S4. However, multiple sources of SCHU S4 have been maintained and propagated independently over the years, potentially generating genetic variants with altered virulence. In this study, the virulence of four SCHU S4 stocks (NR-10492, NR-28534, NR-643 from BEI Resources and FTS-635 from Battelle Memorial Institute) along with another virulent subsp. tularensis strain, MA00-2987, were assessed in parallel. In the Fischer 344 rat model of pneumonic tularemia, NR-643 and FTS-635 were found to be highly attenuated compared to NR-10492, NR-28534, and MA00-2987. In the NZW rabbit model of pneumonic tularemia, NR-643 caused morbidity but not mortality even at a dose equivalent to 500x the LD50 for NR-10492. Genetic analyses revealed that NR-10492 and NR-28534 were identical to each other, and nearly identical to the reference SCHU S4 sequence. NR-643 and FTS-635 were identical to each other but were found to have nine regions of difference in the genomic sequence when compared to the published reference SCHU S4 sequence. Given the genetic differences and decreased virulence, NR-643/FTS-635 should be clearly designated as a separate SCHU S4 substrain and no longer utilized in efficacy studies to evaluate potential vaccines and therapeutics against tularemia.

1 October 2023
Verified
Book Chapter
Closed access
PDF file
SMSherry J. Morgan
Sherry J. Morgan
JHJulie A. Hutt
Julie A. Hutt
RSRadhakrishna Sura
Radhakrishna Sura